Sarepta Therapeutics (SRPT) FY2023 results: revenue $1.2 billion, up 33.3% on the year
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $1.2 billion for fiscal 2023, the year ended 31 December 2023, up 33.3% on the year before. Net income was -$536 million, and diluted earnings per share $-5.80. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2024.
Revenue
$1.2 billion
+33.3% on the year
FY2016FY2023
Operating margin
-21.5%
-57.5% a year earlier
FY2016FY2023
Net income
-$536 million
FY2016FY2023
Diluted EPS
-$5.80
FY2016FY2023
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Operating cash flow
-501
-325
-443
Capital expenditure
76.1
30.8
38.5
+146.9%
Free cash flow
-577
-356
-482
Free cash flow margin
-46.4%
-38.2%
-68.6%
Cash from investing
-166
-1,047
495
Cash from financing
125
233
562
-46.2%
Depreciation and amortisation
44.4
41.9
38.0
+6.1%
Share-based compensation
183
233
114
-21.7%
Buybacks
0.0
n/a
n/a
Diluted shares, weighted
92m
88m
81m
+5.5%
Shares outstanding at period end
94m
88m
87m
+6.6%
Balance sheet
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Shareholders' equity
859
385
928
+123.2%
Debt
1,238
1,544
1,097
-19.8%
Operating lease liabilities
141
57.6
41.5
+144.8%
Other liabilities
1,026
1,142
1,082
-10.1%
Total liabilities and equity
3,265
3,128
3,148
+4.4%
Fixed assets
227
180
191
+26.2%
Intangible assets
29.6
7.6
14.2
+290.9%
Investments
1,248
1,023
0.0
+22.0%
Cash and equivalents
428
967
2,116
-55.7%
Receivables
400
215
153
+86.5%
Inventory
323
204
186
+58.3%
Other assets
608
533
488
+14.2%
Total assets
3,265
3,128
3,148
+4.4%
10-K for the year ended 31 December 2023, filed 28 February 2024: the filing.